Mr. Michael Robert Taylor, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 705 Lena St, Salmon, ID 83467 Phone: 208-756-8515 Fax: 208-756-8385 |
News Archive
Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.
A new trans-Tasman $30 million research commercialisation fund for local universities - announced today in San Diego by Premier of Victoria John Brumby and in New Zealand by New Zealand's Minister for Economic Development Pete Hodgson - will drive research into life-saving medical technology.
A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient's age and disease severity.
Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the imidazoline receptors in the cardiovascular center of the brainstem.
› Verified 4 days ago